Author:
Kan Chen,Yang Jiazhao,Na Ding,Xu Yuanhong,Yang Baixia,Zhao Haodong,Lu Huadong,Li Yuyun,Zhang Keqin,McGuire Tammy L.,Kessler John A.,Kan Lixin
Abstract
Abstract
Heterotopic ossification (HO), true bone formation in soft tissue, is closely associated with abnormal injury/immune responses. We hypothesized that a key underlying mechanism of HO might be injury-induced dysregulation of immune checkpoint proteins (ICs). We found that the earliest stages of HO are characterized by enhanced infiltration of polarized macrophages into sites of minor injuries in an animal model of HO. The non-specific immune suppressants, Rapamycin and Ebselen, prevented HO providing evidence of the central role of the immune responses. We examined the expression pattern of ICs and found that they are dysregulated in HO lesions. More importantly, loss of function of inhibitory ICs (including PD1, PD-L1, and CD152) markedly inhibited HO, whereas loss of function of stimulatory ICs (including CD40L and OX-40L) facilitated HO. These findings suggest that IC inhibitors may provide a therapeutic approach to prevent or limit the extent of HO.
Funder
U.S. Department of Health & Human Services | NIH | Center for Scientific Review
Publisher
Springer Science and Business Media LLC
Subject
Physiology,Histology,Endocrinology, Diabetes and Metabolism
Reference41 articles.
1. Sakellariou, V. I., Grigoriou, E., Mavrogenis, A. F., Soucacos, P. N. & Papagelopoulos, P. J. Heterotopic ossification following traumatic brain injury and spinal cord injury: insight into the etiology and pathophysiology. J. Musculoskelet. Neuron. Interact. 12, 230–240 (2012).
2. Xu, R., Hu, J., Zhou, X. & Yang, Y. Heterotopic ossification: mechanistic insights and clinical challenges. Bone 109, 134–142 (2018).
3. Pacifici, M. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities. Curr. Opin. Pharmacol. 40, 51–58 (2018).
4. Dey, D. et al. The traumatic bone: trauma-induced heterotopic ossification. Transl. Res. 186, 95–111 (2017).
5. Legosz, P., Drela, K., Pulik, L., Sarzynska, S. & Maldyk, P. Challenges of heterotopic ossification-molecular background and current treatment strategies. Clin. Exp. Pharm. Physiol. 45, 1229–1235 (2018).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献